Send PM
Followers 120
Posts 15141
Boards Moderated 2
Alias Born 06/04/2018

Re: None

Tuesday, 07/14/2020 1:00:45 PM

Tuesday, July 14, 2020 1:00:45 PM

Post# of 145
News: $CYAD Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy

Phase 1 clinical trial evaluating the off-the-shelf anti-BCMA CAR T candidate CYAD-211 for the treatment of relapsed/refractory multiple myeloma (r/r MM) expected to begin by year-end 2020 CYAD-211 represents the company’s first allogeneic CAR T clinical candidate using shRNA t...

Read the whole news CYAD - Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYAD News